The Use of Brequinar Sodium for Transplantation^a

Crosstalk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication

“…Both BQR and LFM are immunosuppressive agents, although whether the mechanism of action is solely via pyrimidine inhibition remains controversial and unclear (44)(45)(46). The efficacy of BQR against graft rejection has been investigated extensively in preclinical models (47)(48)(49), and LFM has been proposed as an off-label immunosuppressive therapy in bone marrow (11) and renal (50) transplantation. In addition, DHODH inhibitors have been explored as treatments of other diseases, including malaria, autoimmune and inflammatory dis- eases, cancer, rheumatoid arthritis, and psoriasis (51)(52)(53)(54)(55).…”

Structural Optimization and Structure–Activity Relationship of 4-Thiazolidinone Derivatives as Novel Inhibitors of Human Dihydroorotate Dehydrogenase

“…Brequinar (2), one of the strongest inhibitors of h DHODH, only showed modest anticancer effects on a number of solid tumors in a phase II clinical trial [21,22]. Its effects on autoimmune diseases and viral diseases were also extensively studied [23,24,25]. Vidofludimus (3) was proven to be a promising pharmaceutical agent in systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, and transplantation [7,26,27,28].…”